First Time Loading...

LianBio
NASDAQ:LIAN

Watchlist Manager
LianBio Logo
LianBio
NASDAQ:LIAN
Watchlist
Price: 0.29 USD -3.01% Market Closed
Updated: May 2, 2024

Profitability Summary

LianBio's profitability score is 41/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score
41/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
LianBio

Revenue
0 USD
Operating Expenses
-106.6m USD
Operating Income
-106.6m USD
Other Expenses
18.6m USD
Net Income
-88m USD

Margins Comparison
LianBio Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
LianBio
NASDAQ:LIAN
449.6m USD N/A N/A
US
Abbvie Inc
NYSE:ABBV
285.6B USD
30%
9%
US
Amgen Inc
NASDAQ:AMGN
148.5B USD
29%
24%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.6B USD
39%
37%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
98.8B USD
32%
30%
AU
CSL Ltd
ASX:CSL
133B AUD
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
32%
2%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Moderna Inc
NASDAQ:MRNA
42.6B USD
-62%
-69%
US
Biogen Inc
NASDAQ:BIIB
31.5B USD
22%
12%
KR
Celltrion Inc
KRX:068270
39.3T KRW
30%
25%
Country US
Market Cap 449.6m USD
Operating Margin N/A
Net Margin N/A
Country US
Market Cap 285.6B USD
Operating Margin
30%
Net Margin
9%
Country US
Market Cap 148.5B USD
Operating Margin
29%
Net Margin
24%
Country US
Market Cap 103.6B USD
Operating Margin
39%
Net Margin
37%
Country US
Market Cap 98.8B USD
Operating Margin
32%
Net Margin
30%
Country AU
Market Cap 133B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 81.6B USD
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 42.6B USD
Operating Margin
-62%
Net Margin
-69%
Country US
Market Cap 31.5B USD
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 39.3T KRW
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
LianBio Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
LianBio
NASDAQ:LIAN
449.6m USD
-37%
-29%
-38%
-508%
US
Abbvie Inc
NYSE:ABBV
285.6B USD
35%
4%
16%
13%
US
Amgen Inc
NASDAQ:AMGN
148.5B USD
136%
8%
13%
11%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.6B USD
23%
18%
22%
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
98.8B USD
16%
13%
15%
32%
AU
CSL Ltd
ASX:CSL
133B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
81.6B USD
3%
1%
18%
7%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Moderna Inc
NASDAQ:MRNA
42.6B USD
-29%
-21%
-23%
-41%
US
Biogen Inc
NASDAQ:BIIB
31.5B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
39.3T KRW
5%
4%
6%
4%
Country US
Market Cap 449.6m USD
ROE
-37%
ROA
-29%
ROCE
-38%
ROIC
-508%
Country US
Market Cap 285.6B USD
ROE
35%
ROA
4%
ROCE
16%
ROIC
13%
Country US
Market Cap 148.5B USD
ROE
136%
ROA
8%
ROCE
13%
ROIC
11%
Country US
Market Cap 103.6B USD
ROE
23%
ROA
18%
ROCE
22%
ROIC
44%
Country US
Market Cap 98.8B USD
ROE
16%
ROA
13%
ROCE
15%
ROIC
32%
Country AU
Market Cap 133B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 81.6B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 42.6B USD
ROE
-29%
ROA
-21%
ROCE
-23%
ROIC
-41%
Country US
Market Cap 31.5B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 39.3T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More